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Pn Outline for Public Registration
f Clinical Trials Evaluating Medical Devices
ichard L. Popp, MD, MACC,* Beverly H. Lorell, MD, FACC,† Gregg W. Stone, MD, FACC,‡
arren Laskey, MD, FACC,§ John J. Smith, MD, JD, Aaron V. Kaplan, MD, FACC¶
tanford, California; Indianapolis, Indiana; New York, New York; Albuquerque, New Mexico; Washington, DC;
nd Lebanon, New Hampshire
Public registration of clinical trials is fundamentally important to the integrity of the medical
device development process. In addition to fulfilling obligations to those study volunteers, a
complete record of trial results provides the general public, clinical community, and medical
device manufacturers with a more accurate understanding as to how a specific therapeutic
should be used. Although the issues associated with public disclosure of clinical trials are
similar to the pharmaceutical industries, the iterative nature of device development introduces
differences in what type of information needs to be disclosed during development and
commercialization. The Second Dartmouth Device Development Symposium (3D2) held in
October 2004 brought together thought leaders representing many of the stakeholders
associated with medical device development. This consensus document arising from the
proceedings of the 3D2 is offered to provide background to these issues and recommend
pathways to implementation of device trial registration. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.0791518–21) © 2006 by the American College of Cardiology Foundation
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jecent reports regarding the suppression of data from
linical trials that identified a relationship between
erotonin-reuptake inhibitor antidepressants and suicide in
hildren as well as the connection between cardiovascular
vents in patients taking cyclooxygenase-2 inhibitors has led
o broad public debate regarding the importance of public
egistration of clinical trials (1–3). This has led to congres-
ional hearings, editorials in leading medical journals, and
osition papers from leading medical societies (4–6). The
ocus of these discussions has been primarily on pharma-
euticals, with little attention on the role of public registra-
ion of clinical trials involving medical devices. The Second
artmouth Device Development Symposium (3D2),
eld in October 2004, brought together thought leaders
epresenting many of the stakeholders associated with med-
cal device development (DD). This consensus document
rising from the proceedings of the 3D2 is offered to provide
ackground to these issues and to recommend pathways to
he implementation of device trial registration.
From the *Cardiovascular Medicine Section, Stanford University, Stanford, Cali-
ornia; †Guidant Corporation, Indianapolis, Indiana; ‡The Cardiovascular Research
oundation and Columbia University, New York, New York; §Cardiology Section,
niversity of New Mexico, Albuquerque, New Mexico; Hogan and Hartson, LLP,
ashington, DC; and the ¶Cardiology Section, Dartmouth Medical School and
artmouth-Hitchcock Medical Center, Lebanon, New Hampshire. This paper is a
onsensus document that reflects the opinions of the working group and does not
ecessarily reflect the official policy of the institutions where the authors are employed.
r. Popp is a venture partner at Advance Technology Ventures, a leading venture
apital firm. Dr. Lorell is a corporate officer of a large medical device manufacturer.
r. Stone is a consultant to many venture-backed start-up companies. Dr. Laskey
onsults to the United States Food and Drug Administration. Dr. Smith is a partner
t Hogan and Hartson, which has many medical device manufacturers as clients. Dr.
aplan is a director and holds significant equity positions in several medical device
tart-ups. This paper is the result in part of sessions at the Second Dartmouth Device
evelopment Symposium (3D2) held at the Woodstock Inn, Woodstock, Vermont,
ctober 14 and 15, 2004.m
Manuscript received April 15, 2005; revised manuscript received August 9, 2005,
ccepted September 8, 2005.ACKGROUND
ll those participating in clinical trials seek to advance
edical knowledge to allow us to treat patients more
ffectively. Clinical trials are indispensable for the devel-
pment of new device-based therapies because animal
odels usually do not adequately replicate human anat-
my, physiology, and pathology. Although human re-
earch is necessary, subjects participating in such research
ften derive no direct personal benefit, and in fact,
egative effects of experimental therapies are known to
ccur. It is assumed that the benefit to society balances
he risk for an individual participating in a clinical trial.
he making public of data from clinical trials is funda-
ental to this assumption.
The results of these studies are of deep interest to the
eneral public (including subjects and patients), the clinical
ommunity (including clinicians, investigators, professional
rganizations, journal editors, and conference organizers),
ndustry sponsors (including their shareholders), private
ayers and government (including the U.S. Food and
rug Administration and the Centers for Medicare and
edicaid Services), and the financial community (includ-
ng venture capitalists and public equity markets). There-
ore, it is important that the results of clinical studies be
ade public.
The results of clinical studies may remain unpublished for
any reasons, which include intentional withholding of
ata by sponsors to shield proprietary interests. Further-
ore, publication bias seems to impede the ability to
ublish results of a “negative” trial in a quality peer-reviewed
ournal.
Failure to make public the results of clinical trials has
any implications, which include:
••
•
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mines the public trust that is crucial to the ability to
perform clinical trials going forward
May lead to repeat studies needlessly subjecting new
patients to risk and expending scarce resources
Distorts the knowledge base on which medical care is
determined
When devising the proper mechanism for disclosing
linical trials, one needs to acknowledge the difficulties
ssociated with presentation of raw data that are frequently
omplex, contradictory, and difficult to understand. Fur-
hermore, such a system needs to be implemented without
able 1. Type of Information Disclosed
Early-Stage Safety Trials
nnouncement
What Title of study
Purpose/intent of device to do . . . .
Methods of delivery
(surgical vs. percutaneous)
Sponsor
PI
Start date and expected date of
completion
Number of patients
Number of sites
Title o
Purpo
Study
Metho
(sur
Spons
PI
Numb
Numb
Start d
com
When At date of enrollment of first
patient
At dat
pati
Which studies IDE studies, including OUS
studies, which would require
IDE if performed in the United
States and/or any use that
requires informed consent
All
isclosure
What Major life-threatening or
life-altering adverse events
(presence or absence)
Major
life-
Prima
Major
poin
When In the event of no other public
presentation or reason for
disclosure, the results should be
disclosed within 6 months of
follow-up of the last patient for
the primary end point or within
90 days of premature trial
termination for safety reasons
Conco
of r
Not to
of l
or w
term
In the
pres
disc
up o
poin
trial
Abbreviations and Acronyms
3D2  Second Dartmouth Device Development
Symposium
DD  device developmentDE  investigational device exemption; OUS  outside of the U.S.; PI  principal invesurping the fundamental role of the peer review process
efore formal publication.
ISCUSSION: REPORTING
F MEDICAL DEVICE STUDIES
he issues surrounding the role of public registration of
linical trials in DD were the focus of presentations fol-
owed by roundtable discussion at the 3D2. There was
omplete consensus that both the safety of human subjects
nd informed participation (consent) must be the overriding
thical concerns of all stages of human device experimenta-
ion. The participants also debated the distinctive features of
arly exploratory studies versus later clinical trials, as well as
he similarities and differences between the clinical trial
rocesses of pharmaceutical and device therapies. Discus-
ion focused on which clinical studies should be subject to
ublic registration and what type of data should be dis-
losed.
Pivotal Trials Post-Approval
dy
lation (general description)
delivery
vs. percutaneous)
patients
sites
nd expected date of
n
Title of study
Purpose
Study population (general description)
Methods of delivery
(surgical vs. percutaneous)
Sponsor
PI
Number of patients
Number of sites
Start date and expected date of
completion
nrollment of first At date of enrollment of first
patient
All
Some purely marketing studies of
on-label uses possibly excluded
hreatening or
ng adverse events
point
defined secondary end
Major life-threatening or
life-altering adverse events
Primary end point
Major pre-defined secondary end
points
with first presentation
submission for approval
d 6 months after follow-up
tient for primary end point
90 days of premature trial
on for safety reasons
t of no other public
ion, the results should be
within 6 months of follow-
patient for the primary end
ithin 90 days of premature
ination for safety reasons
Concordant with first presentation
of results submission for approval
Not to exceed 6 months after follow-up
of last patient for primary end point
or within 90 days of premature trial
termination for safety reasons
In the event of no other public
presentation, the results should be
disclosed within 6 months of follow-
up of last patient for the primary end
point or within 90 days of premature
trial termination for safety reasonsf stu
se
popu
ds of
gical
or
er of
er of
ate a
pletio
e of e
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life-t
alteri
ry end
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ts
rdant
esults
excee
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even
entat
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Public Registration of Device Trials April 18, 2006:1518–21There was also consensus among the participants that the
ype of information disclosed should be specific to the stage
f DD being studied (Table 1). However, there was not
omplete agreement regarding the extent of data that should
e disclosed or the appropriate timeframe for its disclosure.
n this context, medical device innovation and development
re frequently characterized by four distinctive stages of
nvestigation:
. Early exploratory human studies examining the feasibility
and safety of a device, typically with secondary efficacy end
points (“first in man” investigation and limited multi-
center studies)
. Hypothesis-driven clinical trials (usually randomized)
testing the final device prototype before regulatory ap-
proval, with primary efficacy end points (“pivotal” studies)
. Post-approval studies and trials that examine new indi-
cations or patient populations differing from the original
device labeling
. Post-approval studies within the device labeling that
examine marketing preferences and behaviors
Early “first-in-man” feasibility studies are initiated after
xtensive bench and animal studies, and are often carried
ut in patients for whom the device may ultimately be
ntended. Such studies typically examine safety using device
rototypes, the results of which often stimulate iterations in
evice design as well as procedural technique. This early
tage of medical device investigation is distinct from early-
tage pharmaceutical studies (phase I studies), in which
afety and pharmacokinetic features of novel drugs are
nitially tested in normal human volunteers. There was
onsensus among the symposium participants that reporting
f safety observations is the overriding issue of public
isclosure during early phases of DD. There was disagree-
ent regarding the extent to which proprietary design
eatures and preliminary measures of efficacy must be
isclosed and introduced into the public domain during
hase I studies.
In contrast to early first-in-man studies, later-stage ran-
omized clinical trials are typically performed to establish
he body of evidence required to support regulatory ap-
roval, reimbursement decisions, and widespread adoption,
ll of which are essential for successful device commercial-
zation. Such pivotal clinical trials are usually characterized
y use of refined devices, testing of predefined hypotheses
egarding primary and secondary end points of safety and
fficacy, pre-specified plans for statistical analysis, and com-
arison of the novel device intervention with a comparator
herapy (placebo or active control). Widespread agreement
as voiced that the results of all pivotal clinical trials should
e available in a public registry to facilitate widespread
issemination and scrutiny.
After approval, when devices are in the marketplace,
egistry studies and/or randomized trials are often per-
ormed to formally examine new indications for use, modes
f application, or safety and efficacy in populations that tiffer from the initial regulatory labeling of the device. The
esults of such studies should be disclosed through national
rial registries in a manner similar to that for pivotal trials.
owever, the symposium participants agreed that such
tudies should be distinguished from post-approval obser-
ational studies, in which the device is used within approved
abeling for the exploration of market preferences relative to
ompetitors.
There was consensus that disclosure of all safety findings
s essential for all clinical device human experimentation,
ncluding those within the four major categories described
arlier. The goal of disclosing the safety results of such
tudies is critical not only for the study subjects, but also for
ubsequent decisions by institutional review boards, physi-
ians, and patients regarding participation in ongoing and
uture studies as well as for the general use of a specific
evice.
We propose that when the first patient is enrolled in any
linical study or trial, there should be an announcement of
he existence and intention of the study, as well as subse-
uent reporting of clinical experiences with emphasis on
isclosure of major life-threatening or life-altering events.
he suggested details of such announcements are outlined
n Table 1.
Later-stage or pivotal clinical trials performed before
egulatory approval, or after approval outside of device
abeling, are done to assess both the safety and the efficacy
f devices, and those results will facilitate choice of devices
nd decisions by physicians and patients regarding subse-
uent therapy. The critical feature here is publication in a
eer-reviewed form of the results of the study within a
easonable period of time. We suggest that such disclosure
e made in every instance and in a timely manner to best
rotect subjects and appropriately impact the activity of
ther clinical trials. The development of reasonable guide-
ines for appropriate timing of the reporting of safety and
fficacy results is complex because accurate reporting de-
ends on both complete ascertainment of outcomes and
ppropriate statistical analysis. Post-approval studies done
ithin the context of labeling of the device for the purpose
f assessing market preferences for a specific device or
esign feature were also debated by the group. Distinct from
ublic reporting of safety outcomes, there was no consensus
egarding the reporting of other results that relate to
ositioning of the device therapy within the competitive
arket environment. Although such data are very interest-
ng to most stakeholders, their primary use in competitive
arketing was seen as a potential problem. The participants
id not fully discuss issues regarding the acquisition and
ublic reporting of actuarial device outcome data acquired in
umans (including claims data), which could potentially
elate to both safety and efficacy.
Additional important issues regarding public disclosure of
edical device trial results, as well as registry of active trial
nrollment, include the appropriate site(s) for repository of
he data, the sources of fair and reasonable funding and
m
r
t
t
f
C
P
t
a
c
c
a
t
a
m
n
m
c
d
r
o
t
A
T
G
S
2
W
L
(
M
J
S
F
a
h
R
C
M
E
R
1
2
3
4
5
6
1521JACC Vol. 47, No. 8, 2006 Popp et al.
April 18, 2006:1518–21 Public Registration of Device Trialsanagement of such databases, and harmonization of public
eporting of clinical trial results acquired in and outside of
he U.S. The mechanisms being implemented for registra-
ion of pharmaceutical trials should be an appropriate venue
or disclosure regarding studies involving medical devices.
ONCLUSIONS
ublic registration of clinical trials is fundamentally impor-
ant to the integrity of the medical device process. In
ddition to fulfilling obligations to study volunteers, a
omplete record of trial results provides the general public,
linical community, and medical device manufacturers with
more accurate understanding regarding how a specific
herapeutic device should be used. Although the issues
ssociated with public disclosure of clinical trials evaluating
edical devices are similar to pharmaceuticals, the iterative
ature of DD introduces differences in what type of infor-
ation needs to be disclosed during development and
ommercialization. It is important to emphasize that public
isclosure should not be viewed as a substitute for peer-
eview publications, which provide a well-developed means
f ensuring that data are presented in a rigorous and
horough fashion.
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